S
TAK icon

SignatureFD’s Takeda Pharmaceutical TAK Stock Holding History

SignatureFD’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Buy
77,725
+7,702
+11% +$127K 0.02% 375
2026
Q1 		$1.3M Buy
70,023
+4,329
+7% +$76K 0.02% 329
2025
Q4 		$1.02M Sell
65,694
-15,089
-19% -$216K 0.02% 370
2025
Q3 		$1.18M Buy
80,783
+1,152
+1% +$17.1K 0.02% 339
2025
Q2 		$1.23M Buy
79,631
+12,052
+18% +$178K 0.02% 308
2025
Q1 		$1M Buy
67,579
+2,482
+4% +$34.8K 0.02% 343
2024
Q4 		$862K Buy
65,097
+19,786
+44% +$272K 0.02% 374
2024
Q3 		$644K Buy
45,311
+10,070
+29% +$143K 0.01% 447
2024
Q2 		$456K Sell
35,241
-14,900
-30% -$197K 0.01% 526
2024
Q1 		$696K Buy
50,141
+10,654
+27% +$155K 0.01% 416
2023
Q4 		$563K Sell
39,487
-3,838
-9% -$54.5K 0.01% 441
2023
Q3 		$670K Sell
43,325
-351
-0.8% -$5.43K 0.02% 355
2023
Q2 		$686K Buy
43,676
+523
+1% +$8.57K 0.02% 349
2023
Q1 		$711K Buy
43,153
+14,538
+51% +$232K 0.02% 325
2022
Q4 		$446K Sell
28,615
-6,688
-19% -$93.4K 0.01% 444
2022
Q3 		$458K Buy
35,303
+10,972
+45% +$153K 0.02% 403
2022
Q2 		$342K Sell
24,331
-10,720
-31% -$153K 0.01% 488
2022
Q1 		$502K Buy
35,051
+13,052
+59% +$192K 0.02% 401
2021
Q4 		$300K Sell
21,999
-1,957
-8% -$27.5K 0.01% 571
2021
Q3 		$392K Buy
23,956
+4,907
+26% +$82.4K 0.01% 454
2021
Q2 		$321K Buy
19,049
+951
+5% +$16.2K 0.01% 500
2021
Q1 		$330K Buy
18,098
+2,018
+13% +$36.3K 0.01% 421
2020
Q4 		$293K Buy
16,080
+1,382
+9% +$24.2K 0.01% 417
2020
Q3 		$262K Buy
14,698
+951
+7% +$17.3K 0.01% 386
2020
Q2 		$246K Buy
13,747
+778
+6% +$14K 0.01% 383
2020
Q1 		$197K Sell
12,969
-4,567
-26% -$82.8K 0.02% 417
2019
Q4 		$346K Buy
17,536
+3,351
+24% +$64.1K 0.03% 321
2019
Q3 		$244K Buy
14,185
+6,810
+92% +$118K 0.02% 358
2019
Q2 		$131K Sell
7,375
-5,831
-44% -$106K 0.01% 528
2019
Q1 		$269K Buy
13,206
+12,676
+2,392% +$255K 0.02% 296
2018
Q4 		$9K Buy
+530
New +$8.95K ﹤0.01% 1395

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

SignatureFD's TAK Position: Q2 2026 in Review

SignatureFD increased its Takeda Pharmaceutical (TAK) stake by 11% in Q2 2026, buying an estimated $127K and bringing the position to 77,725 shares worth $1.25M. The position accounts for 0.02% of the portfolio, ranked #375.

SignatureFD first reported a position in TAK in Q4 2018 and has held it in 31 quarters since. The position peaked at $1.3M in Q1 2026. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • SignatureFD held 77,725 shares of Takeda Pharmaceutical worth $1.25M as of Q2 2026.
  • SignatureFD bought 7,702 Takeda Pharmaceutical shares in Q2 2026, an estimated $127K.
  • Takeda Pharmaceutical made up 0.02% of SignatureFD's portfolio in Q2 2026, its #375 holding.
  • SignatureFD first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 31 quarters since.
  • SignatureFD's Takeda Pharmaceutical position peaked at $1.3M in Q1 2026.
  • 378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.